- Home
- AMPY vs GOSS Comparison
AMPY vs GOSS Comparison
Compare AMPY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- GOSS
- Stock Information
- Founded
- AMPY 2011
- GOSS 2015
- Country
- AMPY United States
- GOSS United States
- Employees
- AMPY N/A
- GOSS N/A
- Industry
- AMPY Oil & Gas Production
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- AMPY Energy
- GOSS Health Care
- Exchange
- AMPY Nasdaq
- GOSS Nasdaq
- Market Cap
- AMPY 265.7M
- GOSS 212.9M
- IPO Year
- AMPY 2011
- GOSS 2019
- Fundamental
- Price
- AMPY $5.76
- GOSS $0.81
- Analyst Decision
- AMPY Strong Buy
- GOSS Strong Buy
- Analyst Count
- AMPY 3
- GOSS 5
- Target Price
- AMPY $10.00
- GOSS $9.20
- AVG Volume (30 Days)
- AMPY 241.3K
- GOSS 2.3M
- Earning Date
- AMPY 11-06-2024
- GOSS 11-07-2024
- Dividend Yield
- AMPY N/A
- GOSS N/A
- EPS Growth
- AMPY N/A
- GOSS N/A
- EPS
- AMPY 1.55
- GOSS N/A
- Revenue
- AMPY $304,645,000.00
- GOSS $105,322,000.00
- Revenue This Year
- AMPY $8.94
- GOSS N/A
- Revenue Next Year
- AMPY N/A
- GOSS N/A
- P/E Ratio
- AMPY $3.69
- GOSS N/A
- Revenue Growth
- AMPY 17.42
- GOSS N/A
- 52 Week Low
- AMPY $3.56
- GOSS $0.50
- 52 Week High
- AMPY $8.15
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- AMPY 30.59
- GOSS 49.87
- Support Level
- AMPY $5.76
- GOSS $0.76
- Resistance Level
- AMPY $6.18
- GOSS $0.88
- Average True Range (ATR)
- AMPY 0.18
- GOSS 0.08
- MACD
- AMPY -0.06
- GOSS 0.01
- Stochastic Oscillator
- AMPY 8.08
- GOSS 30.48
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana, and Eagle Ford.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.